Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 4:31 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 177 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Celecoxib (Celebrex) Clear all
Terminated Phase 2 Interventional

Doxorubicin and Strontium-89 With or Without Celecoxib in Treating Patients With Progressive Androgen-Independent Prostate Cancer and Bone Metastases

NCT00080782
View directory record Official record
Conditions
Metastatic Cancer, Prostate Cancer
Interventions
Celecoxib, Doxorubicin Hydrochloride, Strontium chloride Sr 89
Drug · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Male only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 31, 2018 · Synced Oct 4, 2026, 4:31 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Radiosensitization With Celecoxib and Chemoradiation for Head and Neck Cancer

NCT00581971
View directory record Official record
Conditions
Cancer
Interventions
celecoxib, Carboplatin, Paclitaxel, Radiation Therapy
Drug · Radiation
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2012
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 25, 2013 · Synced Oct 4, 2026, 4:31 PM EDT
Completed Phase 4 Interventional

Efficacy and Safety of Celecoxib Versus Ibuprofen in the Treatment of Osteoarthritis of the Knee (United States)

NCT00620867
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
Ibuprofen, celecoxib, placebo
Drug · Other
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
40 Years and older
Enrollment
393 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
33
States / cities
Anniston, Alabama • Phoenix, Arizona • Anaheim, California + 30 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2021 · Synced Oct 4, 2026, 4:31 PM EDT
Completed Phase 2 Interventional Results available

Open-Label Study Of Exemestane With Or Without Celecoxib In Postmenopausal Women With ABC Having Progressed On Tamoxifen

NCT00038103
View directory record Official record
Conditions
Breast Neoplasms
Interventions
Exemestane, Celecoxib + Exemestane
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Female only
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 25, 2010 · Synced Oct 4, 2026, 4:31 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase I Study to Evaluate Bioavailability of Overencapsulated Celecoxib

NCT00729495
View directory record Official record
Conditions
Healthy Volunteer
Interventions
celecoxib
Drug
Lead sponsor
POZEN
Industry
Eligibility
18 Years to 55 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated May 14, 2009 · Synced Oct 4, 2026, 4:31 PM EDT
Withdrawn Phase 4 Interventional

Celecoxib (Celebrex) in the Management of Acute Renal Colic

NCT00304317
View directory record Official record
Conditions
Ureteral Calculi
Interventions
celecoxib, Placebo
Drug · Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 24, 2017 · Synced Oct 4, 2026, 4:31 PM EDT
Recruiting Phase 2 Interventional

Celecoxib, Durvalumab and Tremelimumab for the Treatment of Patients With Advanced or Metastatic Liver Cancer

NCT07174570
View directory record Official record
Conditions
Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8
Interventions
Celecoxib, Durvalumab, Tremelimumab, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Biopsy Procedure
Drug · Biological · Procedure
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
4
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Oct 4, 2026, 4:31 PM EDT
Terminated Phase 3 Interventional

Perioperative Analgesia on Postoperative Opioid Usage and Pain Control in H&N Cancer Surgery

NCT04176419
View directory record Official record
Conditions
Postoperative Pain Control, Opioid Consumption
Interventions
Ketamine, Placebo Ketamine, Lidocaine, Placebo Lidocaine, Acetaminophen, Placebo Acetaminophen, Gabapentin, Placebo Gabapentin, Celecoxib, Placebo Celecoxib
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 12, 2024 · Synced Oct 4, 2026, 4:31 PM EDT
Terminated Phase 2 Interventional Results available

Comparing Intrathecal Morphine and Intraoperative Lidocaine Infusion to Epidural Anesthesia With Postoperative PCA for Patients Undergoing Exploratory Laparotomy

NCT05017246
View directory record Official record
Conditions
Cancer Debulking, Enlarged Uterus, Fibroid Uterus, Adnexal Mass
Interventions
Bupivacaine, Morphine, Lidocaine
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 31, 2025 · Synced Oct 4, 2026, 4:31 PM EDT
Completed Phase 2 Interventional Results available

Cetuximab & Celecoxib for Metastatic Colorectal Cancer or Colorectal Cancer That Cannot Be Removed by Surgery

NCT00466505
View directory record Official record
Conditions
Colorectal Cancer
Interventions
cetuximab, celecoxib, proteomic profiling, immunohistochemistry staining method, laboratory biomarker analysis, mass spectrometry
Biological · Drug · Genetic + 1 more
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 19, 2012 · Synced Oct 4, 2026, 4:31 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Decreasing Narcotics in Advanced Pelvic Surgery

NCT02110719
View directory record Official record
Conditions
Narcotic Use, Pain, Constipation, Nausea
Interventions
Celebrex, Gabapentin, IV acetaminophen, oral acetaminophen, oral ibuprofen, percocet, vicodin, Oxycodone, dilaudid, Dexamethasone, zofran
Drug
Lead sponsor
Hartford Hospital
Other
Eligibility
18 Years to 100 Years · Female only
Enrollment
138 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 17, 2016 · Synced Oct 4, 2026, 4:31 PM EDT
Completed Phase 2 Interventional Results available

Study of Celebrex (Celecoxib) in Patients With Recurrent Respiratory Papillomatosis

NCT00571701
View directory record Official record
Conditions
Recurrent Respiratory Papillomatosis
Interventions
celebrex (celecoxib), placebo
Drug
Lead sponsor
Northwell Health
Other
Eligibility
2 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
7
States / cities
Birmingham, Alabama • San Francisco, California • Iowa City, Iowa + 4 more
Source: ClinicalTrials.gov public record
Updated May 15, 2017 · Synced Oct 4, 2026, 4:31 PM EDT
Terminated Phase 4 Interventional

Lidocaine Patch Versus Celecoxib in Pain From Osteoarthritis of the Knee

NCT00904605
View directory record Official record
Conditions
Osteoarthritis of the Knee
Interventions
Lidoderm, Celecoxib
Drug
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004
U.S. locations
20
States / cities
Hueytown, Alabama • Mesa, Arizona • Oro Valley, Arizona + 17 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2010 · Synced Oct 4, 2026, 4:31 PM EDT
Terminated Phase 3 Interventional

Celecoxib in Preventing Polyps in Patients Who Have Undergone Surgery for Stage I Colon Cancer

NCT00087256
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Celecoxib, placebo
Drug · Other
Lead sponsor
NSABP Foundation Inc
Network
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 7, 2013 · Synced Oct 4, 2026, 4:31 PM EDT
Completed Phase 3 Interventional Results available

Efficacy Study of PN400 (VIMOVO) Twice Daily and Celebrex Once Daily in Patients With Osteoarthritis

NCT00665431
View directory record Official record
Conditions
Osteoarthritis
Interventions
PN 400 (VIMOVO), celebrex, Placebo, Rescue Antacid
Drug · Other
Lead sponsor
POZEN
Industry
Eligibility
50 Years and older
Enrollment
610 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 6, 2011 · Synced Oct 4, 2026, 4:31 PM EDT
Completed Phase 1 Interventional Results available

Chemokine Modulation Therapy and Standard Chemotherapy Before Surgery for the Treatment of Early Stage Triple Negative Breast Cancer

NCT04081389
View directory record Official record
Conditions
Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Early-Stage Breast Carcinoma, Estrogen Receptor Negative, HER2/Neu Negative, Progesterone Receptor Negative, Prognostic Stage 0 Breast Cancer AJCC v8, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Triple-Negative Breast Carcinoma
Interventions
Celecoxib, Cyclophosphamide, Doxorubicin, Doxorubicin Hydrochloride, Paclitaxel, Recombinant Interferon Alfa-2b, Rintatolimod
Drug · Biological
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Sep 11, 2023 · Synced Oct 4, 2026, 4:31 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Phase I/II Study of Celebrex and EPO906 in Patients With Metastatic Colorectal Cancer

NCT00159484
View directory record Official record
Conditions
Colon Cancer, Colorectal Cancer
Interventions
EPO906, Celecoxib
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Oct 4, 2026, 4:31 PM EDT
Completed Phase 4 Interventional

Effect of Celecoxib Versus Placebo Before and After Knee Surgery on Overall Use of Analgesics After Surgery

NCT00633438
View directory record Official record
Conditions
Arthroscopy
Interventions
Placebo, Celecoxib
Other · Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004
U.S. locations
18
States / cities
Phoenix, Arizona • St. Petersburg, Florida • Baltimore, Maryland + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2021 · Synced Oct 4, 2026, 4:31 PM EDT
Completed Phase 4 Interventional

Efficacy and Safety of Celecoxib Versus Placebo in the Treatment of Patients With Osteoarthritis of the Knee Who Were Unresponsive to Naproxen and Ibuprofen

NCT00640627
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
Celecoxib, Placebo
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
40 Years and older
Enrollment
380 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
30
States / cities
Phoenix, Arizona • Tucson, Arizona • Long Beach, California + 27 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2021 · Synced Oct 4, 2026, 4:31 PM EDT
Terminated Phase 1 Interventional

Tumor Cell Vaccines With ISCOMATRIX Adjuvant and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers and Malignant Pleural Mesotheliomas

NCT01258868
View directory record Official record
Conditions
Mesolthelioma, Esophageal Cancer, Lung Cancer, Thoracic Sarcomas, Thymoma
Interventions
Celebrex, Tumor cell vaccine
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 99 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 3, 2019 · Synced Oct 4, 2026, 4:31 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Zileuton With or Without Celecoxib As Chemopreventive Agents in Smokers

NCT01021215
View directory record Official record
Conditions
Tobacco Use Disorder
Interventions
Zileuton, Celecoxib, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
2
States / cities
New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 2, 2015 · Synced Oct 4, 2026, 4:31 PM EDT
Terminated Phase 2 Interventional Results available

Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma

NCT04093323
View directory record Official record
Conditions
HLA-A2 Positive Cells Present, Refractory Melanoma
Interventions
Alpha-type-1 Polarized Dendritic Cells, Celecoxib, PD-1 Ligand Inhibitor, PD1 Inhibitor, Recombinant Interferon Alfa-2b, Rintatolimod
Biological · Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Feb 25, 2026 · Synced Oct 4, 2026, 4:31 PM EDT
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers Results available

Opioid-Free Pain Protocol After Shoulder Arthroplasty

NCT05488847
View directory record Official record
Conditions
Shoulder Arthropathy, Shoulder Pain
Interventions
Celecoxib, Pregabalin, Tramadol, Dexamethasone, Acetaminophen, Ropivicaine, Epinephrine, Ketorolac, Tizanidine, Magnesium, Ibuprofen, Oxycodone Hydrochloride 5 Mg
Drug
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Oct 4, 2026, 4:31 PM EDT
Terminated Phase 2 Interventional Results available

Celebrex (Celecoxib) Treatment of Laryngeal Papilloma

NCT00592319
View directory record Official record
Conditions
Laryngeal Papilloma
Interventions
Celebrex, PDL, CO2 laser or microsurgery
Drug · Device · Procedure
Lead sponsor
Boston University
Other
Eligibility
18 Years to 64 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 31, 2012 · Synced Oct 4, 2026, 4:31 PM EDT